The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Arix Announces Strategic Review

13 Jul 2023 07:01

Arix Bioscience PLC (ARIX) Arix Announces Strategic Review 13-Jul-2023 / 07:01 GMT/BST


 

The information communicated in this announcement contains inside information for the purposes of article 7 of Regulation (EU) No. 596/2014 as amended and transposed into UK law in accordance with the European Union (Withdrawal) Act 2018, ("MAR"). Upon the publication of this announcement, this information is considered to be in the public domain.

 

Arix Bioscience plc

 

Arix Announces Strategic Review

LONDON, 13 July 2023: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the commencement of a strategic review of the Company’s strategy and assets to assess how the Company can best deliver shareholder value (the “Strategic Review”).

Arix’s investment strategy seeks to deliver significant returns through investment in companies making cutting-edge advances in life sciences. As noted in the Annual Report published on 25 April 2023, the recent period of prolonged uncertainty, volatile market conditions and depressed biotech valuations have resulted in fewer new investments this year with an increased focus on cash conservation.

 

The Board believes that Arix remains well positioned to deliver attractive returns over the long term. However, the Board is conscious of the share price and the significant discount to the Company’s Net Asset Value (“NAV”) per share, despite the Company’s significant net cash balance.

 

The audited NAV of the Company was £226m, £1.75 per share, with a net cash balance of £122.8m as at 31 December 2022 and the unaudited estimated NAV is £241m, £1.86 per share, with a net cash balance of £101m as at 30 June 2023. This discount has occurred during a sustained period of investor risk aversion which has particularly affected the discount applied to unlisted securities across the market as a whole.

 

In response to this and engagement with shareholders following release of the Annual Report, the Board today announces that it has launched the Strategic Review, which will include a consideration of:

the Company's investment and realisation strategies; its capital allocation and shareholder returns policies; and a tax-efficient wind-down of the Company.

 

There is no certainty that any changes will result from the Strategic Review. The Company will make further announcements in due course.

 

The person responsible for arranging the release of this announcement on behalf of the Company is Robert Lyne, Chief Executive Officer.

 

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.
ISIN:GB00BD045071
Category Code:MSCH
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:257307
EQS News ID:1678841
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
28th May 20214:56 pmEQSTransaction in own shares
27th May 20214:58 pmEQSTransaction in own shares
26th May 20214:53 pmEQSTransaction in own shares
25th May 20215:24 pmEQSTransaction in own shares
24th May 20215:04 pmEQSTransaction in own shares
21st May 20215:09 pmEQSTransaction in own shares
20th May 20215:27 pmEQSTransaction in own shares
20th May 20217:00 amEQSChange of registered office
19th May 20215:06 pmEQSTransaction in own shares
18th May 20215:33 pmEQSTransaction in own shares
18th May 20217:00 amEQSNotice of 2021 Annual General Meeting
17th May 20215:40 pmEQSTransaction in own shares
14th May 20215:02 pmEQSTransaction in own shares
13th May 20215:16 pmEQSTransaction in own shares
12th May 20215:12 pmEQSTransaction in own shares
12th May 20214:35 pmEQSAutolus to present additional data in AUTO1 in IBCL 
11th May 20215:43 pmEQSTransaction in own shares
10th May 20215:21 pmEQSTransaction in own shares
7th May 20215:19 pmEQSTransaction in own shares
6th May 20215:23 pmEQSTransaction in own shares
5th May 20215:16 pmEQSTransaction in own shares
4th May 20215:15 pmEQSTransaction in own shares
4th May 20217:00 amEQSTotal Voting Rights
30th Apr 20214:59 pmEQSTransaction in own shares
30th Apr 20217:00 amEQSOutcome of Strategic Implementation Review and Directorate Change
29th Apr 20215:10 pmEQSTransaction in own shares
28th Apr 20215:14 pmEQSTransaction in own shares
28th Apr 202112:02 pmEQSAmplyx Pharmaceuticals acquired by Pfizer
27th Apr 20215:29 pmEQSTransaction in own shares
27th Apr 20212:00 pmEQSLogicBio announces clinical and corporate updates
26th Apr 20215:32 pmEQSTransaction in own shares
23rd Apr 20215:11 pmEQSTransaction in own shares
22nd Apr 20215:15 pmEQSTransaction in own shares
21st Apr 20215:27 pmEQSTransaction in own shares
20th Apr 20215:31 pmEQSTransaction in own shares
19th Apr 20215:09 pmEQSTransaction in own shares
16th Apr 20215:18 pmEQSTransaction in own shares
15th Apr 20215:09 pmEQSTransaction in own shares
14th Apr 20215:13 pmEQSTransaction in own shares
13th Apr 20215:13 pmEQSTransaction in own shares
12th Apr 20215:23 pmEQSTransaction in own shares
9th Apr 20215:44 pmEQSTransaction in own shares
8th Apr 20215:28 pmEQSTransaction in own shares
8th Apr 20218:19 amRNSProactive One2One Virtual Investor Forum
8th Apr 20217:00 amEQSArix to Present at the Proactive One2One Virtual Investor Forum
7th Apr 20215:47 pmEQSTransaction in own shares
7th Apr 20217:00 amEQSArtios announces collaboration with Novartis to create next generation DDR cancer therapies 
6th Apr 20215:26 pmEQSTransaction in own shares
1st Apr 20215:20 pmEQSTransaction in own shares
1st Apr 20217:00 amEQSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.